How to Access Immunotherapy Without Breaking the Bank: Patient Financial Strategies

Recent Trends in Immunotherapy Access and Affordability

Over the past several years, the number of approved immunotherapy regimens has expanded significantly, covering more cancer types and earlier lines of therapy. However, list prices for many of these biologic and cell-based treatments remain high—often ranging from tens of thousands to well over a hundred thousand dollars per year. In response, insurers have started to adjust coverage policies, and a growing number of biosimilar and follow-on products are entering the market. Simultaneously, patient advocacy groups and pharmaceutical manufacturers have expanded financial assistance programs, making it possible for more patients to begin or continue treatment without extreme financial hardship.

Background: Why Immunotherapy Costs So Much

Immunotherapies are complex biologics developed through years of research and clinical trials. Their production involves living systems, which drives manufacturing costs higher than those for small-molecule drugs. Additionally, many are infused in hospital or clinic settings, adding facility fees and professional charges. Oral immunotherapies exist but are often priced similarly. Because patents and exclusivity periods limit competition in the early years, patients and insurers face high prices until biosimilars or alternative agents become available. This structural cost foundation means that even with insurance, out-of-pocket expenses can be substantial.

User Concerns: Common Financial Barriers Patients Face

• High deductibles and annual out-of-pocket maximums that must be met before full coverage kicks in
• Coinsurance percentages (often 20% or more) applied to expensive infused drugs
• Frequent prior authorization requirements, which can delay treatment while appeals are filed
• Limited network options—some immunotherapy centers may be out-of-network, raising patient costs
• Lack of coverage parity between infused and oral immunotherapies under certain insurance plans
• Difficulty qualifying for manufacturer assistance programs due to income or insurance type restrictions

Likely Impact: Strategies That Are Helping Patients

Several financial strategies have shown effectiveness in reducing out-of-pocket burdens. Patient assistance programs run by drug manufacturers can provide free or discounted medications for eligible individuals, often covering a significant portion of annual costs. Independent charitable foundations also offer grants that can be used toward copays, deductibles, or travel expenses. Additionally, enrolling in a clinical trial may provide free access to the immunotherapy agent and related monitoring, though patients should verify coverage of routine care costs. Some hospitals have expanded their own financial assistance policies, offering sliding-scale fees or write-offs for patients with lower incomes. For those whose insurance covers biosimilars, switching to an equivalent lower-cost product can reduce coinsurance amounts. A practical combination of these approaches can lower annual out-of-pocket spending into the range of a few thousand dollars or less for many patients.

What to Watch Next

The landscape of immunotherapy affordability is likely to shift in the coming years. Federal drug price negotiation provisions, such as those in the Inflation Reduction Act, may eventually apply to certain high-spend immunotherapy drugs, potentially lowering list prices for Medicare beneficiaries and indirectly affecting commercial pricing. More biosimilar approvals are expected, which could increase competition and reduce costs. Some states are exploring legislative caps on out-of-pocket spending for specialty drugs, and value-based contracting arrangements between insurers and manufacturers may tie payment to patient outcomes. Patients and providers should monitor these policy developments and revisit financial assistance options regularly, as eligibility criteria and available programs change over time.